États-Unis · Plateformes & données · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Publié par TipRanks · États-Unis il y a 10 h

Résumé détaillé

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

Lire l'article complet sur TipRanks Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.tipranks.com)

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Résumé détaillé

À lire aussi

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Résumé détaillé

Partager

À lire aussi

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says